Compare GKOS & ONON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GKOS | ONON |
|---|---|---|
| Founded | 1998 | 2010 |
| Country | United States | Switzerland |
| Employees | 1094 | N/A |
| Industry | Medical/Dental Instruments | Shoe Manufacturing |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.9B | 12.4B |
| IPO Year | 2015 | 2021 |
| Metric | GKOS | ONON |
|---|---|---|
| Price | $185.49 | $32.22 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 12 | 20 |
| Target Price | ★ $126.92 | $60.15 |
| AVG Volume (30 Days) | 855.1K | ★ 6.8M |
| Earning Date | 04-29-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $507,442,000.00 | N/A |
| Revenue This Year | $23.32 | $19.58 |
| Revenue Next Year | $27.43 | $19.98 |
| P/E Ratio | ★ N/A | $56.05 |
| Revenue Growth | ★ 32.33 | N/A |
| 52 Week Low | $73.16 | $30.11 |
| 52 Week High | $189.69 | $51.08 |
| Indicator | GKOS | ONON |
|---|---|---|
| Relative Strength Index (RSI) | 74.68 | 37.17 |
| Support Level | $99.75 | $31.52 |
| Resistance Level | N/A | $38.63 |
| Average True Range (ATR) | 7.77 | 1.21 |
| MACD | 1.39 | -0.67 |
| Stochastic Oscillator | 88.29 | 23.92 |
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.
Founded in Switzerland in 2010, sportswear firm On Holding generates more than 90% of its sales from athletic shoes. The brand is best known for its running shoes and its distinctive CloudTec soles. On also produces athletic apparel (6% of 2025 sales) and accessories (1%). The firm's merchandise is available in more than 80 countries and is sold through both wholesale (58% of sales) and company-owned channels (42%). In 2025, On generated 58% of its sales in North America, 25% in Europe, the Middle East, and Africa, and 17% in the Asia-Pacific region.